LucentLucent Intel
Sign in
PCVX$66.70-9.6%IOVA$12.96-8.4%MRVI$7.85-7.9%MRNA$187.46-7.8%BHVN$12.08-6.9%MYGN$4.28-6.6%CRSP$54.00-5.8%RCKT$2.48-5.0%ARQT$23.92-4.9%CLPT$11.01-4.4%KROS$11.01-4.4%ANNX$4.03-4.0%PCVX$66.70-9.6%IOVA$12.96-8.4%MRVI$7.85-7.9%MRNA$187.46-7.8%BHVN$12.08-6.9%MYGN$4.28-6.6%CRSP$54.00-5.8%RCKT$2.48-5.0%ARQT$23.92-4.9%CLPT$11.01-4.4%KROS$11.01-4.4%ANNX$4.03-4.0%
Weekly brief·2026-10-05

Merck and IDEAYA face Oct. 10 FDA decisions while Johnson & Johnson earnings test pipeline momentum

Merck and IDEAYA are both lined up for Oct. 10 FDA decisions, with Merck’s setup complicated by the recent withdrawal of an ADC filing and IDEAYA’s framed by investor focus on the small-cell lung cancer ADC landscape. Johnson & Johnson follows with Oct. 13 earnings, where recent psoriasis updates and forecast revisions sharpen attention on pipeline durability and commercial trajectory.

Read the full brief →

Catalysts · Next 3 weeks

What’s on the calendar

$MRKin 3 daysOct 10, 2026
PDUFA·PDUFA: I-DXd — In patients with pretreated extensive-stage small cell lung cancer (ES-SCLC).
$IDYAin 3 daysOct 10, 2026
PDUFA·PDUFA: I-DXd — 2L extensive-stage small cell lung cancer
$JNJin 6 daysOct 13, 2026
Earnings·Johnson & Johnson (JNJ) Earnings — 2026Q4
$IONSin 3 weeksOct 26, 2026
PDUFA·PDUFA: Bepirovirsen — Hepatitis B

Top biopharma news

Live feed

What KOLs and the press are saying

  • news$MRK
    BioSpace·Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market - BioSpace
    20h ago
  • news$JNJ
    ClinicalTrials.gov·A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
    1d ago
  • news$JNJ
    ClinicalTrials.gov·Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
    1d ago
  • news$MRK
    ClinicalTrials.gov·A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
    1d ago
  • KOL$MRK
    @ReadPlaza·$PCVX is up 34% after its VAX-31 pneumococcal vaccine hit every primary endpoint in the Phase 3 OPUS-1 trial. It was compared against Pfizer's Prevnar 20 and Merck's Capvaxive in adults. Vaxcyte plans to file with the FDA in the first half of 2028. https://t.co/ev5qGxzTan
    1d ago
  • KOL$MRK
    @fdzmurillo·@WallStSai $MRK hiring a senior MASH clinical-development lead is interesting — but people seem to be missing where $NVO already stands. Novo is not “entering” MASH. Wegovy is already FDA-approved for MASH F2–F3, with ESSENCE showing: • 63% MASH resolution without worsening fibrosis • 37%
    2d ago
  • KOL$IONS
    @jfais20·@mikeboltsfan thanks Mike, we saw what Baker patience accomplished in $KOD $BCYC has an interesting delivery mechanism, $IONS took advantage of it with tech license deal
    4d ago
  • KOL$JNJ
    @semodough·$JNJ $PTGX ICOTYDE, rates of clear or almost clear skin (Investigator’s Global Assessment [IGA] 0/1)c increased from 57% at Week 16 to 67% at Week 24 and 70% at Week 112. • At Week 112, high rates of site-specific complete skin clearance were reported among ICOTYDE-treated https://t.co/5X77J6NCkH
    4d ago
  • KOL$JNJ
    @semodough·$JNJ $PTGX Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy https://t.co/fUEnLxXcUw
    4d ago
  • KOL$IDYA
    @BiopharmIQ·#ESMO2026 is around the corner, and we’re going to hear a lot about ADCs. Our Q4 watchlist tracks 10 catalysts across $TAK, $MGNX, $IDYA, $BHVN, $KYNB, $AZN, and $ADCT, from conference data to an FDA decision. Which could shift the investment case? Read the blog: https://t.co/ikQYE9tDXw https://t.co/NMZHEQwm9a
    5d ago
  • KOL$MRK
    @Quantumup1·BTIG⬇️ $CNTB's PT to $5 from $10 and reit'd Buy after Seabreeze STAT COPD met its 1° endpoint of reduction in Tx failure rate, w/ 0 pts in the rademikibart Tx arm returning to the hospital or ED. $SNY - REGN VRNA - $MRK GSK AZN TRVI INSM UTHR LQDA BTIG said in its note: CNTB https://t.co/ufQLaprr2A
    6d ago

What is Lucent

Catalyst-anchored biopharma intelligence.

Lucent is a biopharma intelligence platform. It monitors X, SEC filings, clinical trial disclosures, and analyst commentary — anchored to the catalyst calendar — and publishes a weekly synthesis.

Signal extraction

Every analyst post, FDA filing, and earnings call parsed and scored in minutes.

Catalyst calendar

1,200+ tracked events: PDUFAs, AdComs, readouts, earnings, conferences.

Cross-trial efficacy

Normalized endpoints across competing drug programs. Compare apples to apples.

Read-through alerts

Watch one ticker. Get alerted when something hits a related drug or peer.

See Lucent chat

Ask a real question. Get a cited answer.

Question
How does Rezdiffra's real-world launch trajectory compare to expectations?

Bottom line: Rezdiffra's launch appears at least in line with, and likely ahead of, prior expectations on the commercial metrics Lucent surfaces. The platform's compiled view labels execution "on track," and the freshest primary-source update available says Q1 2026 net sales reached $311.3M, with >42,250 active patients and patient count up 2.5x vs 1Q25. That is consistent with a launch that has moved beyond a cautious specialty rollout into broad physician adoption.

Why I say that

  • Lucent's Rezdiffra wiki explicitly characterizes commercial execution as strong: trailing-12-month net sales exceeded $1.1B, demand remained strong, and management framed the launch as tracking "in line with or exceeding" best-in-class specialty launches.
  • The wiki is recent — compiled 2026-06-02 — so this is not an obviously stale take.
  • The platform was thin on recent launch news/posts, so I checked the web. Madrigal's May 6, 2026 release says Rezdiffra had $311.3M Q1 2026 sales and >42,250 patients on therapy, while reiterating confidence in "robust growth expectations" for 2026.
  • An external prescription-trends paper supports the idea that uptake has been meaningful in the real world, though it covers only through Nov. 2025 and is based on pharmacy-fill data rather than full net-sales economics.

Footnotes

  1. Resmetirom — Lucent wiki (compiled 2026-06-02)

  2. Madrigal Pharmaceuticals — Q1 2026 earnings release

  3. National trends in resmetirom prescriptions for MASH — Clin Mol Hepatol

Continue the answer in chat →

Ask ChatGPT the same question and you’ll get: Rezdiffra had a strong initial launch as the first approved MASH drug and analysts were generally positive on uptake. For specific quarterly sales figures or the latest patient counts, I'd recommend checking Madrigal's investor relations page or a recent earnings summary.

Hit rate85.7%· N=788
Tracked X accounts23
Ticker wikis124
Drug wikis140

Pilot launching this quarter

We’re inviting a small group of biopharma traders to the alpha. Tell us about your workflow and we’ll be in touch.